Saturday, 10 May 2025
  
Login

Australia's most trusted
source of pharma news

Saturday, 10 May 2025
News

Will Amgen's $42b play pay off?

Posted 14 December 2022 AM

Amgen has closed the biggest biotech deal of 2022 to buy Dublin-based Horizon Therapeutics for AUD$42 billion, a move which could see drugs for rare diseases become available to Australians.

Horizon has no medicines registered on the Australian Register of Therapeutic Goods. While Amgen did not provide much detail for its plans with Horizon, one of the reasons it gave for the acquisition was that it has a global scale to enhance the growth potential of Horizon's portfolio.

To see the whole article, please login

Popular

What downturn? Pharma is back
How leaders can fix disengagement
Who's industry's 'Most Influential'?
Drug flood overwhelming HCPs
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home